Trial Profile
A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral arterial occlusive disorders; Peripheral artery restenosis; Peripheral ischaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms IMPERIAL
- Sponsors Boston Scientific Corporation
- 29 Jul 2022 Status changed from active, no longer recruiting to completed.
- 22 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Dec 2022.
- 05 Nov 2019 Results presented in the VIVA Physicians media release.